This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Ziprasidone in the Psychosis Prodrome (ZIP)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT00635700
First received: March 6, 2008
Last updated: September 6, 2016
Last verified: September 2016
March 6, 2008
September 6, 2016
March 2008
November 2012   (Final data collection date for primary outcome measure)
Conversion to Psychosis [ Time Frame: 6 months ]
Conversion to psychosis according to the SIPS require psychotic symptom severity ratings in the frankly psychotic range, along with meeting persistence or urgency criteria.
Conversion to Psychosis [ Time Frame: 6 months ]
Complete list of historical versions of study NCT00635700 on ClinicalTrials.gov Archive Site
Improvement SOPS Total Score [ Time Frame: 8 weeks ]
Same as current
Not Provided
Not Provided
 
Ziprasidone in the Psychosis Prodrome
Ziprasidone vs Placebo in the Prevention of Psychosis Among Symptomatic Adolescents and Young Adults at Prodromal Risk
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Psychosis Prodrome
  • Drug: ziprasidone
    20-160 mg/d
    Other Name: Geodon
  • Drug: placebo
    placebo
  • Experimental: 1
    Intervention: Drug: ziprasidone
  • Placebo Comparator: 2
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
66
November 2012
November 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • SIPS criteria for psychosis prodrome
  • clinically referred

Exclusion Criteria:

  • prolonged QTc
  • history of syncope
Sexes Eligible for Study: All
16 Years to 40 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT00635700
0801003386
IIR GA1281GE
Yes
Not Provided
Not Provided
Not Provided
Yale University
Yale University
Not Provided
Principal Investigator: Scott W Woods, MD Yale University
Yale University
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP